EXO-CD24 may potentially be used as a novel treatment to suppress the hyper-inflammatory response in the lungs of severely affected COVID-19-associated ARDS patients, as well as in other systemic diseases where cytokine storm is developed. The gene discussed is CD24; the disease is COVID-19.